Table 1 The relationship between F2RL1 expression and the clinical characteristics of CCa.
Characteristics | Low expression of F2RL1 | High expression of F2RL1 | P-value |
|---|---|---|---|
Age, n (%) | Â | Â | 0.481 |
 <  = 50 | 91 (29.7%) | 97 (31.7%) |  |
 > 50 | 62 (20.3%) | 56 (18.3%) |  |
n | 153 | 153 | Â |
Race, n (%) | Â | Â | 0.178 |
Asian | 10 (3.8%) | 10 (3.8%) | Â |
Black or African American | 20 (7.7%) | 11 (4.2%) | Â |
White | 98 (37.5%) | 112 (42.9%) | Â |
Pathologic T stage, n (%) | Â | Â | 0.882 |
T1 | 71 (29.2%) | 69 (28.4%) | Â |
T2 | 38 (15.6%) | 34 (14%) | Â |
T3 | 10 (4.1%) | 11 (4.5%) | Â |
T4 | 4 (1.6%) | 6 (2.5%) | Â |
Pathologic N stage, n (%) | Â | Â | 0.359 |
N0 | 71 (36.4%) | 63 (32.3%) | Â |
N1 | 28 (14.4%) | 33 (16.9%) | Â |
Pathologic M stage, n (%) | Â | Â | 0.551 |
M0 | 62 (24.2%) | 54 (21.1%) | Â |
M1 | 7 (2.7%) | 4 (1.6%) | Â |
MX | 63 (24.6%) | 66 (25.8%) | Â |
Clinical stage, n (%) | Â | Â | 0.958 |
Stage I | 83 (27.8%) | 79 (26.4%) | Â |
Stage II | 33 (11%) | 36 (12%) | Â |
Stage III | 22 (7.4%) | 24 (8%) | Â |
Stage IV | 11 (3.7%) | 11 (3.7%) | Â |
Primary therapy outcome, n (%) | Â | Â | 0.700 |
PD | 10 (4.6%) | 13 (5.9%) | Â |
SD | 4 (1.8%) | 2 (0.9%) | Â |
PR | 3 (1.4%) | 5 (2.3%) | Â |
CR | 89 (40.6%) | 93 (42.5%) | Â |
Histological type, n (%) | Â | Â | 0.001 |
Adenocarcinoma | 12 (3.9%) | 35 (11.4%) | Â |
Adenosquamous | 4 (1.3%) | 2 (0.7%) | Â |
Squamous cell carcinoma | 137 (44.8%) | 116 (37.9%) | Â |
PFI event (Progression-Free Interval), n (%) | Â | Â | 0.007 |
No | 127 (41.5%) | 107 (35%) | Â |
Yes | 26 (8.5%) | 46 (15%) | Â |
